QNCX · As filed with the SEC
Quince Therapeutics cash flow statement, by quarter
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net Income | — | 35,912,000 | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock based compensation | — | 1,286,000 | — | — |
| Depreciation and amortization | — | 36,000 | — | — |
| Change in the fair value of contingent consideration liabilities | — | (64,330,000) | — | — |
| Change in fair value of debt, net | — | (12,197,000) | — | — |
| Change in fair value of warrants | — | (31,116,000) | — | — |
| Gain on settlement of accounts payable | — | (2,584,000) | — | — |
| Intangible asset impairment charge | — | 67,808,000 | — | — |
| Amortization of discount on available-for-sale investments | — | (62,000) | — | — |
| Changes in operating assets and liabilities, net of acquisitions: | ||||
| Prepaid expenses and other current assets | — | (3,639,000) | — | — |
| Right of use assets, operating leases and operating lease liabilities | — | 28,000 | — | — |
| Other assets | — | 1,782,000 | — | — |
| Accounts payable | — | 5,911,000 | — | — |
| Accrued expenses and other current liabilities | — | (7,163,000) | — | — |
| Other liabilities | — | 701,000 | — | — |
| Net cash used in operating activities | — | (7,627,000) | — | — |
| Cash flow from investing activities: | ||||
| Purchase of investments | — | 0 | — | — |
| Proceeds from maturities of investments | — | 12,000,000 | — | — |
| Purchase of property and equipment | — | 0 | — | — |
| Net cash provided by investing activities | — | 12,000,000 | — | — |
| Cash flows from financing activities: | ||||
| Proceeds from issuance of common stock upon exercise of stock options | — | 0 | — | — |
| Issuance of common stock in connection with the ATM offerings, net of issuance costs | — | 14,988,000 | — | — |
| Repayment of debt | — | (5,545,000) | — | — |
| Net cash provided by financing activities | — | 9,443,000 | — | — |
| Effect of exchange rate changes on cash | — | (1,462,000) | — | — |
| Net increase in cash and cash equivalents | — | 12,354,000 | — | — |
| Cash and cash equivalents at beginning of period | 18,163,000 | 5,809,000 | 6,452,000 | 16,826,000 |
| Cash and cash equivalents at end of period | 115,981,000 | 18,163,000 | 5,809,000 | 6,452,000 |
| Supplemental disclosures of cash flow and non-cash information: | ||||
| Cash paid for interest | — | (29,000) | — | — |
| Noncash exercise of pre-funded warrants | — | 340,000 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.